NGM Bio subject of take-private bid by institutional investor The Column Group

NGM Bio, with a spate of clinical setbacks and financial woes in recent years, has received an unsolicited acquisition bid from shareholder The Column Group.

The life science venture fund owns 26.7% of the biotech’s shares, according to a Dec. 28 SEC filing. The Column Group…
Click here to view original post